WALTHAM, Mass., April 14, 2015 (GLOBE NEWSWIRE) -- TESARO, Inc. (Nasdaq:TSRO), an oncology-focused biopharmaceutical company, today announced two upcoming presentations related to its immuno-oncology portfolio.
-
The Company will participate in the Jefferies 2015 Immuno-Oncology Summit at the Boston Harbor Hotel on April 15, 2015. Mary Lynne Hedley, Ph.D., President and COO of TESARO, will discuss the Company's immuno-oncology programs in a presentation scheduled for 2:00 PM ET.
-
TESARO and AnaptysBio will present preclinical data in a poster session at the American Association for Cancer Research (AACR) Annual Meeting in Philadelphia, April 18-22, 2015. Presentation details are as follows:
Sunday, April 19, 2015, 1:00 p.m. to 5:00 p.m. ET
"Targeting PD-1, TIM-3 and LAG-3 in Combination for Improved Immunotherapy Combinations"
Abstract Number: 271, Location: Section 12.
For more information, including the presentation abstract, please visit the AACR website at www.aacr.org.
About TESARO
TESARO, Inc. is an oncology-focused biopharmaceutical company dedicated to improving the lives of cancer patients.